Matches in SemOpenAlex for { <https://semopenalex.org/work/W641199610> ?p ?o ?g. }
Showing items 1 to 67 of
67
with 100 items per page.
- W641199610 abstract "Introduction: Multiple sclerosis (MS) is an autoimmune disease that causes the demyelination and subsequent degeneration of axons. Approximately 18 000 individuals suffer from MS in Sweden.Aim: The aim was to describe drug utilization patterns of new oral MS drugs and to investigate what factors (e.g., patient characteristics, reimbursement restrictions) might explain the observed utilization patterns. Methods: This was an observational population-based study of all MS drugs users residing in Stockholm County. Data analyses were conducted at the aggregate level and at the individual level. Patients initiated on any MS drug were selected from the VAL database between 1 November 2011 and 31 October 2014. Characteristics of patients were compared using ANOVA and chi-square test.Results: Since the introduction of new oral drugs the use of Avonex started decreasing while the use of Gilenya and Tecfidera increased proportionally. The use of Betaferon, Copaxone and Rebif was also declining. Aubagio and Extavia were virtually not used at all. The sex (p = 0.3687) and age distribution (p= 0.1961) did not differ between patients treated with injectable therapies and those who started on Gilenya or Tecfidera. All patients were seen by a specialist, but differences were observed in the use of other healthcare resources, namely admission to hospitals (p = 0.0085) and visits to the primary care practice (p = 0.0424). No differences were found in the prevalence of pain and comedications use between the users of injectable therapies, Gilenya and Tecfidera (p = 0.4998).Conclusions: Avonex was commonly used in MS patients. Gilenya and Tecfidera were rapidly adopted since their introduction. The use of Aubagio had been limited due to its risk-benefit profile and reimbursement restriction. Analyses of characteristics of patients who initiated on injectable MS drugs, Gilenya and Tecfidera indicate that these populations were similar in terms of age, sex distribution, comorbidities and comedications used." @default.
- W641199610 created "2016-06-24" @default.
- W641199610 creator A5011047032 @default.
- W641199610 date "2015-01-01" @default.
- W641199610 modified "2023-09-27" @default.
- W641199610 title "UTILIZATION PATTERNS OF NEW ORAL MULTIPLE SCLEROSIS DRUGS" @default.
- W641199610 hasPublicationYear "2015" @default.
- W641199610 type Work @default.
- W641199610 sameAs 641199610 @default.
- W641199610 citedByCount "0" @default.
- W641199610 crossrefType "journal-article" @default.
- W641199610 hasAuthorship W641199610A5011047032 @default.
- W641199610 hasConcept C126322002 @default.
- W641199610 hasConcept C160735492 @default.
- W641199610 hasConcept C162324750 @default.
- W641199610 hasConcept C203014093 @default.
- W641199610 hasConcept C23131810 @default.
- W641199610 hasConcept C2779134260 @default.
- W641199610 hasConcept C2779703844 @default.
- W641199610 hasConcept C2780035454 @default.
- W641199610 hasConcept C2780640218 @default.
- W641199610 hasConcept C2908647359 @default.
- W641199610 hasConcept C50522688 @default.
- W641199610 hasConcept C71924100 @default.
- W641199610 hasConcept C98274493 @default.
- W641199610 hasConcept C99454951 @default.
- W641199610 hasConceptScore W641199610C126322002 @default.
- W641199610 hasConceptScore W641199610C160735492 @default.
- W641199610 hasConceptScore W641199610C162324750 @default.
- W641199610 hasConceptScore W641199610C203014093 @default.
- W641199610 hasConceptScore W641199610C23131810 @default.
- W641199610 hasConceptScore W641199610C2779134260 @default.
- W641199610 hasConceptScore W641199610C2779703844 @default.
- W641199610 hasConceptScore W641199610C2780035454 @default.
- W641199610 hasConceptScore W641199610C2780640218 @default.
- W641199610 hasConceptScore W641199610C2908647359 @default.
- W641199610 hasConceptScore W641199610C50522688 @default.
- W641199610 hasConceptScore W641199610C71924100 @default.
- W641199610 hasConceptScore W641199610C98274493 @default.
- W641199610 hasConceptScore W641199610C99454951 @default.
- W641199610 hasLocation W6411996101 @default.
- W641199610 hasOpenAccess W641199610 @default.
- W641199610 hasPrimaryLocation W6411996101 @default.
- W641199610 hasRelatedWork W1506120110 @default.
- W641199610 hasRelatedWork W1522056646 @default.
- W641199610 hasRelatedWork W1698877338 @default.
- W641199610 hasRelatedWork W2019446948 @default.
- W641199610 hasRelatedWork W2042186321 @default.
- W641199610 hasRelatedWork W2076290890 @default.
- W641199610 hasRelatedWork W2115538350 @default.
- W641199610 hasRelatedWork W2127809083 @default.
- W641199610 hasRelatedWork W2145920263 @default.
- W641199610 hasRelatedWork W2314982100 @default.
- W641199610 hasRelatedWork W2741002512 @default.
- W641199610 hasRelatedWork W2904039091 @default.
- W641199610 hasRelatedWork W2905220597 @default.
- W641199610 hasRelatedWork W2914099159 @default.
- W641199610 hasRelatedWork W2947497059 @default.
- W641199610 hasRelatedWork W3088566781 @default.
- W641199610 hasRelatedWork W3126716594 @default.
- W641199610 hasRelatedWork W3157997408 @default.
- W641199610 hasRelatedWork W3173117651 @default.
- W641199610 hasRelatedWork W2105733577 @default.
- W641199610 isParatext "false" @default.
- W641199610 isRetracted "false" @default.
- W641199610 magId "641199610" @default.
- W641199610 workType "article" @default.